MedTrace Logo

Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO

NCT00566761 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-05-30

No results posted yet for this study

Summary

Treatment of macular edema secondary to central retinal vein occlusion is more effective with combined therapy of bevacizumab and triamcinolone than bevacizumab alone.

Conditions

  • Macular Edema
  • Central Retinal Vein Occlusion

Interventions

DRUG

bevacizumab and triamcinolone

three applications monthly administrated of bevacizumab 2.5mg for group 1 and bevacizumab 2.5 mg + triamcinolone 4mg first dose followed by two of bevacizumab alone for the group 2

Sponsors & Collaborators

  • Asociación para Evitar la Ceguera en México

    lead OTHER

Principal Investigators

  • Carmen Gonzalez-Mijares, Physician · Asociación para Evitar la Ceguera en México

  • Hugo Quiroz-Mercado, Retinologyst · Asociación para Evitar la Ceguera en México

  • Juan Manuel Jimenez Sierra, Retinologyst · Asociación para Evitar la Ceguera en México

  • MA Martinez-Castellanos, Physician · Asociación para Evitar la Ceguera en México

  • Octavio Burgos Vejar, Physician · Asociación para Evitar la Ceguera en México

  • Raul Velez-Montoya, Physician · Asociación para Evitar la Ceguera en México

  • Ma de Lourdes Lopez Ramos, Physician · Asociación para Evitar la Ceguera en México

  • Omar Honerlager, preresident · Asociación para Evitar la Ceguera en México

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2007-06-30
Completion
2008-03-31

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00566761 on ClinicalTrials.gov